Syndax Stock Plunges 16% on Phase II Fibrosis Study Failure

Key Facts

1Syndax shares dropped 16% after its Phase II study of axatilimab missed the primary endpoint.

2The company decided to abandon development of the drug for idiopathic pulmonary fibrosis following the results.

Syndax shares dropped 16% after its Phase II study of axatilimab missed the primary endpoint. Zacks reported that the company decided to abandon the development of the drug for idiopathic pulmonary fibrosis following these clinical results.

The clinical trial failure led to the termination of the specific development program, impacting investor confidence in the company's pipeline. The stock experienced a sharp downward trend following the announcement.